Velcura meets with FDA to discuss development plans

Michigan, USA-based biotechnology company Velcura Therapeutics says it has met with the Food and Drug Administration to clarify details for the early clinical development of VEL0230, a candidate bone disease treatment. The pre-Investigational New Drug application meeting covered feedback of preclinical work that the firm has already completed, as well as near-term clinical development plans.

Velcura said that it plans to initiate clinical trials of the drug in 2008 as a therapy for the blood cancer multiple myeloma, which is associated with significant bone loss.